Glucagon-like peptide 1: Continued advances, new targets and expanding promise as a model therapeutic

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 1, 2007, Pages 68-73

  Aulinger, Benedikt ^a   D'Alessio, David ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Beta cell mass; Gastrointestinal hormones; Glucose tolerance; Incretin; Insulin secretion

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1[9-36]; INSULIN RECEPTOR SUBSTRATE 2; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; BRAIN REGION; CELL GROWTH; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; EXPERIMENTAL MODEL; FOOD INTAKE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART OUTPUT; HEART PROTECTION; HUMAN; IMMUNE RESPONSE; INSULIN RELEASE; INTESTINE CELL; LIVER METABOLISM; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INTESTINES; NUTRITION PHYSIOLOGY; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 33847758675     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328013e79e     Document Type: Review

References (50)

1. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36 (11-12):867-876.
2. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55:243-251. This paper reveals the physiologic effects of GLP-1 on glucose metabolism in humans. Here it was demonstrated for the first time that endogenous GLP-1 is a physiologic incretin in humans and plays an important role in postprandial antropyloro-duodenal motility.
3. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20:876-913.
4. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165. This is an excellent and comprehensive review of incretin biology. It outlines all important findings that contribute to the current understanding of incretin biology and discusses up-to-date publications on GLP-1 signaling and its effects beyond being an incretin.
5. Eissele R, Goke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pigandman. Eur J Clin Invest1992; 22:283-291.
6. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97:92-103.
7. Herrmann C, Goke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56:117-126.
8. Dube PE, Brubaker PL. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res 2004; 36 (11-12):755-760.
9. Le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108-114. This publication systematically analyzes the changes in gut hormone profiles after diverse techniques of bariatric surgery and reflects on their contribution to the observed weight loss.
10. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240:236-242.
11. Koopmans HS, Sclafani A. Control of body weight by lower gut signals. Int J Obes 1981; 5:491-495.
12. Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005; 288:E447-E453. This work shows for the first time that GLP-1 and PYY at least partially mediate the previously established effects of ileal transposition surgery on food intake and body weight.
13. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36 (11-12):761-765.
14. Meier JJ, Gethmann A, Nauck MA, et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006; 290:E1118-E1123. This recent study rejuvenates the controversy over the biological effects of the degraded major metabolite GLP-1(9-36).
15. Deacon CF, Plamboeck A, Moller S, Holst JJ. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002; 282:E873-E879.
16. Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88:1772-1779.
17. Zander M, Madsbad S, Deacon CF, Holst JJ. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 2006; 49:369-374. The findings of this study, which demonstrate a lack of effects of endogenous GLP-1(9-36) on glucose metabolism in patients with diabetes, are highly relevant in the light of DPP-IV inhibition as a drug target.
18. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77:257-270.
19. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379:69-72.
20. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 1996; 271 (4 Pt 2):R848-R856.
21. Thiele TE, Van Dijk G, Campfield LA, et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol Regul Integr Comp Physiol 1997; 272 (2 Pt 2):R726-R730.
22. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol Regul Integr Comp Physiol 1999; 277 (5 Pt 2):R1537-R1540.
23. Seeley RJ, Blake K, Rushing PA, et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20:1616-1621.
24. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002; 22:10470-10476.
25. Lachey JL, D'Alessio DA, Rinaman L, et al. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 2005; 146:458-462. This study underlines the importance of species differences in animal models and points to the limits of transgenic mouse models to determine universal mammalian (GLP-1) physiology.
26. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000; 279:R1449-R1454.
27. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50:1720-1728.
28. Ionut V, Liberty IF, Hucking K, et al. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol Endocrinol Metab 2006; 291:E779-E785. This paper raises interesting questions about how GLP-1 physiologically mediates its incretin effects.
29. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115:3554-3563. In this comprehensive study investigating the role of GLP-1 in the CNS, it has been shown for the first time that central GLP-1 controls peripheral glucose utilization. These findings illustrate the novel mechanisms by which GLP-1 contributes to glucose homeostasis and underline how peripheral and CNS physiology are integrated in GLP-1 physiology.
30. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol 1993; 265 (4 Pt 1):L374-L381.
31. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137:2968-2978.
32. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Physiol 1994; 266 (3 Pt 1):E459-E466.
33. Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol Endocrinol Physiol 1999; 277 (5 Pt 1):E784-E791.
34. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110:43-52.
35. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144:2242-2252.
36. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965.
37. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215.
38. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110:955-961.
39. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289:H2401-H2408. The novelty in this paper is the apparent activity of GLP-1(9-36) on glucose metabolism and cardiac function in dogs.
40. Nikolaidis LA, Doverspike A, Hentosz T, et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005; 312:303-308. This study adds to the literature demonstrating the positive effects of GLP-1 on myocardial function by demonstrating a protective effect on ischemia in a clinically relevant animal model.
41. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54:146-151. This careful study uses in-vivo and ex-vivo models to demonstrate that at least some GLP-1 effects on the heart are directly mediated through myocardial GLP-1r. This paper also identifies the outline of important intracellular signaling by the GLP-1r.
42. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48:2270-2276.
43. Wang X, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 2001; 142:1820-1827.
44. MacDonald PE, Salapatek AM, Wheeler MB. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002; 51 (Suppl 3):S443-S447.
45. Wang Q, Li L, Xu E, et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004; 47:478-487.
46. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005; 48:1339-1349. This report builds on previous work by this group, demonstrating the importance of PKB to mediate GLP-1 effects in β cells, and extends the findings to cytokine toxicity, a model relevant to type 1 diabetes.
47. -/- mice convincingly demonstrate that IRS2 is necessary for the growth effects of GLP-1 but not the effects to acutely stimulate insulin secretion.
48. Buteau J, Spatz ML, Accili D. Transcription factor Fox01 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006; 55:1190-1196. In this paper convincing evidence is provided that Fox01 is a major downstream mediator of GLP-1-activated PKB. This is a novel mechanism in GLP-1 signaling but is consistent with other information on Fox01 and the role of PKB.
49. Wideman RD, Yu IL, Webber TD, et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci U S A 2006; 103:13468-13473. The importance of this paper is as a proof of concept for a gene therapy approach that could conceivably be applied to human islet transplantation.
50. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146:2069-2076. This paper raises the important point that islet mass, like insulin secretion, must be viewed in the context of prevailing insulin sensitivity.